Israeli medical device company, Hospitech Respiration, has developed a respiratory guard system which reduces ventilation complications in intubated patients and minimises the exposure of clinical teams to contamination.
The AnapnoGuard consists of an automatic control unit (AG100s) and a proprietary multi lumen endotracheal tube, which prevents complications such as hospital acquired pneumonia, ventilator associated pneumonia and injury to the trachea.
More than 600 people have been treated with the device, including ventilated COVID-19 patients at the Tongji University Hospital in China’s Hubei Province, the original epicentre of the pandemic.
In Israel, it has been used in several leading hospitals, including Rambam MC, the largest academic centre in northern Israel. It has also been sent to two hospitals in southern Italy.
WHY IT MATTERS
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The AnapnoGuard device provides automated airway cuff pressure management and automated evacuation of the subglottic secretions, reducing the likelihood of pulmonary infections and the development of pneumonia that can tend to develop in ventilated patients, including severe COVID-19 ventilated patients.
In cases where an infection has already developed, it alleviates the symptoms and helps to shorten the recovery time.
THE LARGER CONTEXT
Hospitech Respiration also offers other airway management products, including AG Cuffill, a disposable manometer for airway cuff pressure management.
Source: Mobihealth News